Drugs / 89Zr-panitumumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04833959 | Mar 2021 → Mar 2024 | malignant pancreatic neoplasm | Stanford University | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05423197 | Jun 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | Stanford University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-panitumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04833959 ↗ |
| Modality | Diagnostic / imaging agent | “molecular imaging agent” NCT04833959 ↗ |
| Route | Intravenous | “Subjects will be given 89Zr-panitumumab IV” NCT05423197 ↗ |